One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

Annals of Oncology ◽

10.1093/annonc/mdx362.004 ◽

2017 ◽

Vol 28 ◽

pp. v45 ◽

Cited By ~ 3

Author(s):

X. Pivot ◽

I.M. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study ◽

One Year

Download Full-text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.072 ◽

2018 ◽

Vol 93 ◽

pp. 19-27 ◽

Cited By ~ 29

Author(s):

X. Pivot ◽

I. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Reference Product ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.lba4 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. LBA4-LBA4 ◽

Cited By ~ 33

Author(s):

Martine J. Piccart-Gebhart ◽

Andrew Peter Holmes ◽

Jose Baselga ◽

Evandro De Azambuja ◽

Amylou C. Dueck ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Phase Iii ◽

Her2 Positive ◽

First Results ◽

One Year

Download Full-text

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

The Oncologist ◽

10.1634/theoncologist.2018-0065 ◽

2018 ◽

Vol 23 (10) ◽

pp. 1137-1143 ◽

Cited By ~ 5

Author(s):

Kyung Hae Jung ◽

Beyhan Ataseven ◽

Mark Verrill ◽

Xavier Pivot ◽

Michelino De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Medical Conditions ◽

Her2 Positive ◽

Subgroup Analyses ◽

Breast Cancer Subgroup ◽

Phase Iii Study

Download Full-text

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

The Breast ◽

10.1016/s0960-9776(21)00097-7 ◽

2021 ◽

Vol 56 ◽

pp. S21-S22

Author(s):

J. Gligorov ◽

X. Pivot ◽

B. Ataseven ◽

M. De Laurentiis ◽

A. Llombart ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial

Download Full-text

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.056 ◽

2021 ◽

Vol 32 ◽

pp. S37-S38

Author(s):

O. Metzger ◽

C. Lambertini ◽

I.E. Krop ◽

G. Lewis Phillips ◽

C.M. Perou ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Biomarker Analysis ◽

Phase Iii Study

Download Full-text

Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

Annals of Oncology ◽

10.1093/annonc/mdx362.003 ◽

2017 ◽

Vol 28 ◽

pp. v44-v45 ◽

Cited By ~ 3

Author(s):

F.J. Esteva ◽

Y. Baranau ◽

V. Baryash ◽

A. Manikhas ◽

V. Moiseyenko ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc)

Annals of Oncology ◽

10.1093/annonc/mdu438.2 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 2

Author(s):

E.A. Perez ◽

E. Holmes ◽

E. De Azambuja ◽

A. Dueck ◽

J. Baselga ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Disease Free Survival ◽

Phase Iii ◽

Her2 Positive ◽

Free Survival ◽

Disease Free

Download Full-text

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.800 ◽

2021 ◽

Author(s):

J. Huober ◽

C.H. Barrios ◽

N. Niikura ◽

M. Jarzab ◽

Y-C. Chang ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

European Journal of Cancer ◽

10.1016/s0959-8049(16)30904-2 ◽

2015 ◽

Vol 51 ◽

pp. S318

Author(s):

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

H.A. Azim ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Lower Body ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

Subgroup Analyses ◽

Phase Iii Study

Download Full-text

0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy

The Breast ◽

10.1016/s0960-9776(09)70169-9 ◽

2009 ◽

Vol 18 ◽

pp. S53

Author(s):

M. Gnant ◽

B. Mlineritsch ◽

P. Dubsky ◽

C. Menzel ◽

W. Schippinger ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Multicentre Phase ◽

Phase Iii Study

Download Full-text